PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35451495-0	2022	AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells.	Cisplatin	39-48	arylacetamide deacetylase	Homo sapiens	0-5	
26882803-6	2015	The DAC treatment deteriorated the CDDP-induced viability decreasing Caki or ACHN cells and synergized the apoptosis induction of CDDP in ACHN cells.	Cisplatin	35-39	arylacetamide deacetylase	Homo sapiens	4-7	
26882803-6	2015	The DAC treatment deteriorated the CDDP-induced viability decreasing Caki or ACHN cells and synergized the apoptosis induction of CDDP in ACHN cells.	Cisplatin	130-134	arylacetamide deacetylase	Homo sapiens	4-7	
26882803-9	2015	CONCLUSIONS: The present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.	Cisplatin	175-179	arylacetamide deacetylase	Homo sapiens	46-49	
26882803-9	2015	CONCLUSIONS: The present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.	Cisplatin	223-227	arylacetamide deacetylase	Homo sapiens	46-49	
35451495-9	2022	Both cisplatin and imatinib suppressed cancer cell malignant progression, while overexpressed AADAC synergistically enhanced such inhibition.	Cisplatin	5-14	arylacetamide deacetylase	Homo sapiens	94-99